ARQT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 25533 min ago

@ $12.30

Išleistas: 11 bal. 2024 @ 19:30

Grąža: -31.14%

Ankstesnis signalas: bal. 11 - 17:25

Ankstesnis signalas: Pardavimas

Grąža: -0.89 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	2.16M
Vidutinė apimtis	4.19M
Rinkos kapitalizacija	973.80M
EPS	$0 ( 2024-02-27 )
Kita pelno data	( $-0.650 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.24
ATR14	$0.0130 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Topper David Joseph	Buy	310 000	Stock Option (right to buy)
2024-04-10	Topper David Joseph	Buy	110 000	Common Stock
2024-04-10	Topper David Joseph	Sell	7 500	Stock Option (right to buy)
2024-03-04	Matsuda Masaru	Sell	3 760	Common Stock
2024-03-04	Burnett Patrick	Sell	4 782	Common Stock

INSIDER POWER
30.75
Last 98 transactions
Buy: 3 267 821 \| Sell: 1 662 580

Tūris Koreliacija

Ilgas: -0.52 (weak negative)

Trumpas: 0.75 (moderate)

Signal:(32.698) Neutral

Arcutis Biotherapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RCKY	0.919
MORN	0.915
WBA	0.911
CPTN	0.907
CSSE	0.905
PENN	0.903
CNSL	0.902
ENNV	0.901
CSTE	0.898
NYMT	0.897

10 Labiausiai neigiamai susiję koreliacijos
OBT	-0.916
PRGS	-0.915
HTBI	-0.914
NWPX	-0.911
KTCC	-0.909
VC	-0.907
HUBG	-0.897
JBSS	-0.889
WSC	-0.889
PRN	-0.886

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Arcutis Biotherapeutics Koreliacija - Valiuta/Žaliavos

0.39
( neutral )

0.30
( neutral )

0.00
( neutral )

-0.25
( neutral )

0.47
( neutral )

-0.02
( neutral )

Arcutis Biotherapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$59.61M
Bruto pelnas:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2023
Pajamos:	$59.61M
Bruto pelnas:	$53.49M (89.74 %)
EPS:	$-3.78

FY	2022
Pajamos:	$3.69M
Bruto pelnas:	$2.93M (79.54 %)
EPS:	$-5.84

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5.79

Financial Reports:

No articles found.

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.